为解决 FLT3-ITD AML 患者治疗效果不佳及耐药难题，上海临港实验室的研究人员开展关于 IHCH9033 与 FLT3 抑制剂联合治疗的研究，发现二者协同增效且能克服耐药。推荐科研读者阅读，以了解该领域前沿成果。 上海临港实验室（Lingang Laboratory）的研究人员 Mingyue Yao ...

此前,吉瑞替尼于2020年7月获得中国国家药品监督管理局的优先审评资格 [1],并在2020年11月被列入第三批临床急需境外新药名单 [2],在加速通道下,于2021年1月30日被NPMA附条件批准上市。

Internal tandem duplication (ITD) mutation in Fms-like tyrosine kinase 3 gene (FLT3/ITD) represents an unfavorable genetic change in acute myeloid leukemia (AML) and is associated with poor prognosis.

今日（1月18日），中国国家药监局药品审评中心（CDE）官网最新公示，第一三共（Daiichi Sankyo）申报的5.1类新药盐酸奎扎替尼片上市申请获得受理。公开资料显示，这是一款FLT3抑制剂Vanflyta（quizartinib），已经于2023年7月获美国FDA批准治疗带有FLT3-ITD突变阳性的新确诊急性髓系白血病（AML）成人患者，它用于AML患者三个治疗阶段——诱导、巩固和维持治 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

Several compounds targeting FLT3 internal tandem duplication (ITD) have been developed in the past decades, but none has overcome myelosuppressive toxicity caused by the simultaneous inhibition of ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance therapy for treating newly diagnosed FLT3-ITD-positive AML, an indication ...

Tim Kong et al, RSK1 dependency in FLT3-ITD acute myeloid leukemia, Blood Cancer Journal (2024). DOI: 10.1038/s41408-024-01187-4 Provided by Washington University in St. Louis ...